SecBot SecBot
SC 13G ·Filed Nov 10, 2026

SLS

SELLAS Life Sciences Group, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed7d 7h ago SEC0000093751-26-000723
Passive investor 5%+ stake
Actionable Insight • Neutral

State Street's passive stake is consistent with its role as an index fund manager and does not signal activist intent. Monitor for any future 13D conversion or material changes in position size in subsequent filings.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$8.37
T+0 close · Nov 10, 2026 · via day close
Latest settled
+0.60%
T+1 · $8.42
Vs SPY
−0.72%
α at T+1
Next horizon
T+5
due 10h ago
  1. T+0 · Nov 10 $8.37entry
  2. T+1 · 6d ago +0.60%α −0.72% · $8.42
  3. T+5 · due 10h ago Pending
  4. T+5 · todayOpen
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

State Street Corp filed a Schedule 13G disclosing a 5.1% passive beneficial ownership stake in SELLAS Life Sciences Group as of September 30, 2026, representing 10,373,074 shares. This is an amendment to a prior 13G filing from August 2026, indicating a continued passive position with no intent to influence control.

Key Financial Metrics

Stake
5.1%
Investor
STATE STREET CORP

Key Facts

  • State Street Corp disclosed a 5.1% passive beneficial ownership stake in SELLAS Life Sciences Group
  • Stake consists of 10,373,074 shares of common stock as of September 30, 2026
  • Filing is an amendment to a prior Schedule 13G filed on August 7, 2026
  • State Street certifies the securities were acquired and held in the ordinary course of business with no intent to influence control
  • State Street is a bank holding company filing under Rule 13d-1(b)

Financial Impact

5.1% passive stake valued at approximately $86.7 million based on market cap of $1.7B

ownership

Risk Factors

  • No material risks identified from this routine passive stake filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G Filing (Primary)0000093751-26-000723
Document: 0000093751-26-000723-index.html0000093751-26-000723
Document: 0000093751-26-000723.txt0000093751-26-000723

Track record

16 reports on SLS

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 17, 2026today 424B5 Bearish 6/10 Entry $16.40 Now $19.15 −16.74% settles Feb 17
  2. Nov 17, 2026today Press Release Bearish 6/10 Entry $18.59 Now $19.15 −3.01% settles Feb 17
  3. Nov 17, 2026today 8-K Bullish 7/10 Entry $7.75 Now $19.15 +147.10% settles Feb 16
  4. Nov 17, 2026today Press Release Bullish 8/10 Entry $7.75 Now $19.15 +147.10% settles Feb 16
  5. Nov 12, 20265d ago 8-K Neutral 5/10 Entry $7.86 Now $19.15 +143.64% settles Feb 11
  6. Nov 10, 20267d ago SC 13G Neutral 3/10 Viewing Entry $8.37 Now $19.15 +128.79% settles Feb 8
  7. Nov 3, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.87 Now $19.15 +115.90% settles Feb 1
  8. Oct 28, 202620d ago Press Release Mixed 7/10 Entry $10.38 Now $19.15 +84.49% settles Jan 26
  9. Oct 27, 202621d ago SC 13G/A Neutral 3/10 Entry $10.38 Now $19.15 +84.49% settles Jan 26
  10. Sep 25, 20267w ago Press Release Neutral 3/10 Entry $11.61 Now $19.15 +64.94% settles Dec 21
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (16h 52m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026